Reltio Unveils Industry-First Solution to Serve Trusted, Unified Data in Milliseconds at Every Point of Engagement, Driving Customer Experience Excellence
Reltio®, a leader in data unification and management, today announced the launch of the Reltio Lightspeed™ Data Delivery Network, a groundbreaking innovation that powers real-time applications and personalized customer experiences with unified data—served in less than 50 milliseconds globally.
Customer experiences are no longer confined to a store, office, or branch. We live in a hyper-connected world where engagement happens everywhere—on mobile apps, kiosks, and even in our cars. Consumers expect personalization in every context, whether visiting a doctor, booking a hotel room, buying a car, or ordering fast food. Many companies, however, struggle to deliver real-time, high-quality data at the point of engagement, forcing them to build costly, complex infrastructure, often failing to provide accurate, trusted data where and when needed.
“Customer engagement and conversion no longer happen in the rearview mirror—they happen in the moment,” said Ansh Kanwar, Reltio’s EVP of Product, Technology, and Strategy. “Reltio Lightspeed Data Delivery Network solves this by instantly delivering API-ready data anywhere in under 50 milliseconds, eliminating service complexity so businesses can focus on what matters most—delivering seamless digital experiences and real-time engagement that gives them a competitive edge.”
Instant, Reliable, and Scalable Data Access
Reltio’s Lightspeed Data Delivery Networkis designed to empower global, cross-functional teams with unparalleled speed and reliability, enabling businesses to:
- Access critical data globally in under 50 milliseconds, ensuring seamless performance for real-time, customer-facing, and other business-critical applications.
- Reduce infrastructure costs by leveraging query-optimized, in-memory datasets in a simplified service architecture.
- Improve core data availability and resilience via optional multi-region deployments.
Kanwar added, “There is a pressing need for real-time data across every industry. For example, Reltio’s retail customers want data close to their point-of-sale systems spread across the globe, our hospitality customers want a seamless experience for loyalty programs delivered through mobile apps, and payment processors want to ensure the shortest possible time to transaction processing for payments. Reltio provides data in real time for all of these use cases.”
Enhanced Capabilities in Reltio Data Cloud
Reltio also introduced powerful new features to Reltio Data Cloud, further enhancing data security, scalability, and accessibility across the globe. Reltio Data Cloud now offers cutting-edge features to enhance data privacy, unification, and usability, including:
- Data masking: Protects sensitive data with configurable granular controls and role-based access control (RBAC) to improve compliance and security.
- Bulk-match review: Acceleratesdata unification and increases data team productivity by enabling the review of thousands of potential matches in bulk and resolving up to 100 potential data matches simultaneously.
- Reverse geocoding: Converts complex location data into easy-to-read, verifiable addresses, helping businesses streamline operations, expand targeted marketing reach, and enhance customer satisfaction.
Reltio Data Cloud helps enterprises solve their most challenging data problems—at an immense scale—and enables AI-driven innovation across their organizations. Reltio Data Cloud today processes 61.1B total API calls per year and has 9.1B consolidated profiles under management, 100B relationships under management, and users across 140+ countries.
Availability
Reltio Lightspeed Data Delivery Network and Reltio Data Cloud are available now. For more information, read the 2025.1 release blog post by our product team.
About Reltio
At Reltio, we believe data should accelerate the speed of business and fuel your success. Our AI-powered data unification and management offerings deliver unified, trusted data where and when it’s needed so that enterprises can be responsive to changing business needs. Reltio Data Cloud™ encompasses our entire ecosystem of solutions, including Reltio Customer 360™, Multi-Domain Master Data Management (MDM), and Entity Resolution. Reltio Data Cloud unifies disparate data sources in real-time, creating a single, trusted source of truth. Leading enterprise brands across multiple industries around the globe rely on our award-winning data unification and management capabilities to improve efficiency, manage risk, and drive growth.
“Reltio” is a registered trademark, and “Reltio Customer 360”, “Reltio Data Cloud,” and “Reltio Lightspeed”, are trademarks of Reltio, Inc. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225862603/en/
Contacts
Alan Ryan
Allison Worldwide for Reltio
Reltio@allisonworldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom